Sanofi, Alnylam Win First RNAi Approval for Hemophilia A and B

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless of the presence of neutralizing antibodies against clotting factor VIII or IX.

Scroll to Top